Finger Lakes
Finger Lakes
The glacial lakes of upstate New York. Carved deep and narrow, holding cold water in a landscape that has learned how to endure disruption and remain.
A gut that holds its ground.
The only beneficial yeast with decades of clinical research.
Rich and creamy. A clean, mild flavor. Our everyday classic.
Richer, with a deeper and more complex flavor. For those who want more from every jar.
Our richest and thickest. Cold-strained for maximum culture concentration.
Produced in a home kitchen under the Wyoming Food Freedom Act — not inspected by the state or a local health department. For informed consumers only.
*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
Not a bacterium. A yeast. And that changes everything.
Eukaryotic yeast · Kingdom Fungi
Every other culture in the Vital line is a bacterium. Finger Lakes is a yeast. That is not a cosmetic distinction. It is the reason Finger Lakes can do something no other product can: remain fully active during an antibiotic course.
The story of its discovery is worth telling. In 1923, Henri Boulard — a French microbiologist working in Indochina — observed a cholera epidemic moving through the region. Most people in the affected areas developed the severe diarrhea associated with cholera. But people who were consuming lychee and mangosteen fruit seemed to be affected differently. Boulard isolated an organism from the skin of these fruits and identified it as the protective agent. That organism was Saccharomyces boulardii — named in his honor.
S. boulardii is closely related to Saccharomyces cerevisiae — the same species used in bread baking and brewing for millennia. Some taxonomists classify it as a culture of S. cerevisiae rather than a separate species; the debate is ongoing. What is not debated is its fundamental cellular architecture: it is a eukaryote. It has a membrane-bound nucleus. Its ribosomes are 80S — the same as human cells. Its cell wall is made of chitin and glucan, not the peptidoglycan that bacteria use. This cellular architecture is the structural basis for its antibiotic immunity.
"Boulard was not looking for a probiotic. He was looking for why some people were not getting sick. The answer turned out to be a yeast on the surface of tropical fruit — and nearly a century of clinical research has since confirmed what he observed in the field."
Why antibiotics cannot touch it — the structural explanation.
Antibiotics are designed with specificity. They target structures that exist in bacteria but not in human cells — primarily the bacterial cell wall (peptidoglycan) and the bacterial ribosome (70S). This selectivity is what makes them safe for humans while lethal to bacteria.
Yeast have neither of these targets. Their cell walls contain chitin and beta-glucan — structures that beta-lactam antibiotics (penicillins, cephalosporins), glycopeptides (vancomycin), and cell wall-active drugs cannot bind. Their ribosomes are 80S — macrolides, tetracyclines, aminoglycosides, and fluoroquinolones that inhibit bacterial 70S ribosomes have no binding affinity for eukaryotic ribosomes. Antifungal medications (fluconazole, amphotericin) would affect S. boulardii — but those are separate drugs used for separate purposes. Standard antibacterial antibiotics are simply incapable of harming it.
The conditions that make S. boulardii irreplaceable.
S. boulardii is a transient organism — unlike the bacteria in the rest of the Vital line, it does not permanently colonize the gut. It establishes, does its work, and is cleared within days of stopping consumption. That transient nature is not a limitation. It is precisely why it is suited for the conditions where it matters most.
The gut microbiome functions as an ecosystem. Like any ecosystem, it has resilience — a capacity to absorb disruption and recover. But that resilience is not unlimited. Antibiotic treatment, acute illness, significant dietary disruption, and high-stress travel all challenge the microbiome in ways that can push it past its natural recovery capacity. The result is a prolonged period of dysbiosis — imbalance — that can persist for months after the initial disruption, far longer than most people realize.
S. boulardii is the organism specifically designed — by evolutionary selection, and validated by over 80 clinical trials — to hold the gut environment stable during precisely these conditions. It does not replace the bacteria that antibiotics eliminate. It maintains the conditions that allow those bacteria to recover faster once treatment ends.
What S. boulardii does, and how.
Five distinct mechanisms — each contributing to the gut stability that clinical trials have consistently documented.
S. boulardii secretes a 54-kilodalton serine protease — an enzyme that physically cleaves and inactivates Clostridioides difficile toxins A and B. C. difficile is the pathogen responsible for the most common and most severe form of antibiotic-associated colitis. Its toxins bind to specific receptors on intestinal epithelial cells, triggering inflammation and cell death. The S. boulardii protease breaks down the toxins before they can bind — a direct molecular defense that no bacterial probiotic can replicate through the same mechanism.
S. boulardii produces a protein that specifically stimulates the production of secretory IgA (sIgA) in intestinal mucosal tissue. Secretory IgA is the primary antibody of the gut immune system — it coats the mucosal surface and neutralizes pathogens before they can adhere to epithelial cells. In a gut depleted by antibiotics, sIgA levels often drop sharply. S. boulardii's stimulation of sIgA production during and after antibiotic treatment helps maintain this critical first line of mucosal defense.
Several pathogenic organisms — including E. coli and C. difficile — use mannose-containing surface structures to adhere to gut epithelial cells as the first step in infection. S. boulardii expresses cell surface mannose-binding proteins that compete directly for these same binding sites. By occupying mannose receptors on the epithelial surface, S. boulardii physically blocks pathogen adhesion — not through toxin production or immune stimulation, but through direct spatial competition.
S. boulardii reduces NF-κB activation in intestinal epithelial cells in response to pathogenic bacterial products — specifically lipopolysaccharide (LPS) and peptidoglycan fragments that accumulate during antibiotic-driven dysbiosis. By dampening this inflammatory signaling, S. boulardii reduces the intestinal inflammation associated with antibiotic-associated diarrhea and allows the gut environment to remain more stable during and after treatment.
By maintaining the mucosal immune defense, suppressing pathogen colonization, and reducing intestinal inflammation during antibiotic courses, S. boulardii creates a more favorable environment for the recovery of beneficial bacterial populations once antibiotic treatment ends. Studies following microbiome composition after antibiotic courses show faster restoration of bacterial diversity in subjects who received S. boulardii throughout treatment compared to those who did not.
Published research. Read it yourself.
S. boulardii has over 80 published clinical trials — one of the most studied single organisms in probiotic research. Four of the most significant studies.
Read the detail
A systematic review and meta-analysis pooling data from 31 randomized controlled trials of S. boulardii in adult patients across multiple indications: antibiotic-associated diarrhea, C. difficile-associated disease, traveler's diarrhea, acute diarrhea, and other gastrointestinal conditions. The meta-analysis examined efficacy, safety, and the dose-response relationship across the literature.
S. boulardii demonstrated significant efficacy across multiple indications — most strongly for antibiotic-associated diarrhea (relative risk reduction of approximately 50%) and traveler's diarrhea. The safety profile was excellent across all 31 trials with no serious adverse events in immunocompetent adults. The meta-analysis concluded that S. boulardii was among the most evidence-supported probiotic interventions available for gastrointestinal disruption.
Read the detail
A randomized controlled trial in patients with recurrent C. difficile infection — one of the most clinically challenging antibiotic-associated conditions, characterized by high rates of relapse after antibiotic treatment. Participants were treated with antibiotic therapy (vancomycin or metronidazole) combined with either S. boulardii or placebo. The primary outcome was recurrence of C. difficile infection within the follow-up period.
Patients receiving high-dose vancomycin combined with S. boulardii had a significantly lower rate of C. difficile recurrence compared to those receiving vancomycin plus placebo. The S. boulardii group showed a recurrence rate approximately half that of the placebo group in the high-dose vancomycin arm. The study provided direct clinical evidence for S. boulardii's C. difficile-specific protective mechanisms, consistent with the laboratory findings on toxin neutralization.
Read the detail
One of the largest trials ever conducted on probiotic prevention of traveler's diarrhea — a condition affecting 20 to 60 percent of international travelers and caused by exposure to unfamiliar pathogenic organisms. Over 3,000 Austrian travelers to high-risk destinations received either S. boulardii or placebo, taken throughout their travel period and for a defined period after return.
S. boulardii supplementation produced a statistically significant reduction in the incidence of traveler's diarrhea across all destinations studied. The protective effect was consistent across different geographic regions and different pathogenic exposures — suggesting that S. boulardii's mechanism (competitive exclusion of binding sites, toxin neutralization, sIgA stimulation) provides broad-spectrum protection rather than protection against specific organisms.
Read the detail
A mechanistic study from Harvard Medical School examining how S. boulardii interacts with C. difficile toxin A — the primary toxin responsible for antibiotic-associated colitis. Researchers examined whether S. boulardii's protective effects were due to direct toxin neutralization, receptor competition, or indirect immune effects, and isolated the specific molecular mechanism responsible.
S. boulardii produced a 54-kilodalton serine protease that directly cleaved and inactivated C. difficile toxin A, preventing it from binding to intestinal epithelial receptors. When the protease was isolated and applied independently, it retained the same toxin-neutralizing activity — confirming that direct enzymatic degradation of the toxin was the primary protective mechanism. This study established the molecular basis for S. boulardii's documented clinical efficacy against C. difficile-associated disease.
Note: PubMed links use search queries rather than direct DOIs. Identify the correct paper by author, journal, and year. All studies described are published peer-reviewed research. Vital Yogurts is not affiliated with any research institutions cited.
Honest about what to expect.
S. boulardii is the most situationally specific culture in the Vital line. Its value is highest when the gut is under pressure. What you notice depends significantly on whether that pressure is present.
-
1
During an antibiotic course — the most important use case
Take Finger Lakes throughout your antibiotic course — starting on day one, not after it ends. The bacteria in your gut are being killed by the antibiotic. S. boulardii is not. It continues to produce its protective protease, stimulate secretory IgA, and maintain mucosal defense throughout treatment. People who take S. boulardii during antibiotics report significantly less digestive disruption, faster return to normal gut function after the course ends, and reduced incidence of the antibiotic-associated diarrhea that many people simply accept as inevitable.
-
2
During travel — gut stability in unfamiliar environments
Traveler's diarrhea affects between 20 and 60 percent of international travelers depending on destination. The Kollaritsch trial documented a significant protective effect in over 3,000 travelers. The mechanism — competitive exclusion of pathogen binding sites and broad-spectrum toxin neutralization — is not destination-specific. Finger Lakes is the culture to start a week before travel and continue throughout.
-
3
After disruption — faster recovery
After illness, a course of antibiotics, or a period of significant dietary disruption, the microbiome typically requires weeks to months to fully recover its pre-disruption diversity and composition. S. boulardii's presence during recovery — maintaining sIgA levels, suppressing pathogen colonization of the recovering epithelium, and reducing inflammatory signaling — supports a faster and more complete return to baseline microbiome health.
-
4
As a daily maintenance culture — sustained continuity
Daily Finger Lakes use between disruption events maintains a baseline of gut protection and sIgA support that makes each disruption less damaging when it comes. Think of it less as a reactive intervention and more as insurance — the value is highest when the event it protects against occurs, but the protection is in place throughout. For frequent travelers, anyone who takes periodic antibiotics, or anyone whose diet varies significantly, this is the culture worth maintaining year-round.
Our Live Fermented Milks are genuinely potent — in a way you won't find in store-bought products. When you introduce a large number of live beneficial cultures into a microbiome that has grown quieter over time, your body notices. Some people feel temporary bloating or mild discomfort in the first hour or two after their first few servings. This is your body adjusting. It passes. Start with two to four ounces and pay attention to how you feel before adding more. The daily ritual builds over weeks, not hours.
Finger Lakes completes the first month.
Finger Lakes arrives with Blue Ridge in the second delivery. By day 15, Acadia and Glacier have established the foundation. Finger Lakes and Blue Ridge complete it — daily maintenance and stability, side by side.
The oxytocin-vagus nerve culture. Emotional balance, restful nights, gut barrier integrity.
First Delivery — Days 1–14 Glacier B. coagulans / B. subtilisSpore-forming cultures. Digestive regularity, post-exercise recovery, and Vitamin K2.
Second Delivery — Days 15–30 Blue Ridge Lactobacillus gasseriThe metabolic culture. Small intestinal colonization, GLP-1 signaling, and daily digestive ease.
Four cultures. Two deliveries. Thirty days. The formal 30-day guarantee applies to this bundle — because thirty days of daily use is what the science is built around.